Partial SAA patients benefit from delayed response of IST.

ABSTRACT:

Introduction

Severe aplastic anemia(SAA)is a severe disease characterized by immune-mediated bone marrow failure and pancytopenia. Immunosuppressive therapy (ATG plus CsA, IST) is the standard treatment for patients who are not suitable for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Some patients have a delayed response after 6 months of ATG, and unnecessary to be given secondary ATG or allo-HSCT. We attempted to distinguish patients who may get potential delayed response from those who were really not responsive to IST.

Methods

We collected data from 45 SAA patients who were assessed no-response to IST at 6 months after rATG and failed to receive secondary ATG or allo-HSCT.

Results

CsA plus eltrombopag (EPAG) group has an extra 75% response rate

SUBMITTER: Wang T 

PROVIDER: S-EPMC9951814 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature